Compare Gilead Sciences, Inc. (GILD) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street SPDR S&P Homebuilders ETF — how do they compare? Gilead Sciences, Inc. trades at $136.55 (market cap $163.51B), while State Street SPDR S&P Homebuilders ETF trades at $110.79. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals.
| GILD | XHB | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $121.36 |
52-Week Low | $108.22 | $94.86 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
The SPDR S&P Homebuilders ETF (XHB) is trading at $110.05, up 1.75% on the day, with a bullish technical signal from moving averages. The ETF is positioned to potentially benefit from new housing legislation, though recent data shows a mixed housing market with declining existing home sales and record-high prices. Key technical support is at $107-$108, with resistance at $110-$111.
The outlook for XHB hinges on housing market dynamics amid high mortgage rates. The recent Landmark Housing Affordability Bill could provide a catalyst for homebuilder stocks. However, risks include persistent high rates, volatile construction spending, and sensitivity to broader economic conditions. Investor sentiment is cautiously optimistic, focused on legislative tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
